Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032$6,989.00 – $20,967.00
Growth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032$6,989.00 – $20,967.00
We see great future treatment opportunity for the NMOSD market because of the launch of the emerging therapies like Telitacicept (RC-Pharma), Ravulizumab (Alexion Pharmaceuticals), SHR1459 (Reistone Biopharma) and others potential therapies, providing the global solution for “optic neuritis with spinal cord manifestations and other neurologic disorders associated with the serum aquaporin-4 immunoglobulin G antibodies”.
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032$6,989.00 – $20,967.00
The Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2022 to 2032. In 2022, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2018 to 2032.
Lumbar Radiculopathy (Sciatica)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032$6,989.00 – $20,967.00
The Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032$6,989.00 – $20,967.00
Corticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
Complex regional pain syndrome (CRPS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032$6,989.00 – $20,967.00
Complex regional pain syndrome (CRPS) is a chronic pain condition characterized by spontaneous and evoked regional pain, usually starting in a distal extremity, which is disproportionate in magnitude or duration to the typical pain course after similar tissue trauma. Current treatment for CRPS requires a multidisciplinary approach involving patient education, physical and occupational therapy, psychiatry and pain medicine specialists, along with pharmacological and surgical interventions. Unfortunately, the current available treatment options are generally considered to be ineffective and one-dimensional, as they only treat part of the disease. Emerging therapies like Soticlestat (Takeda / Ovid Therapeutics and Lanicemine (AstraZeneca / Biohaven Pharmaceuticals) is expected to generate more market share than other emerging therapies and have the potential to overcome the treatment barrier.
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022$2,700.00 – $8,100.00
Anti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
Filter by price
Top rated products
- Metabolic Disorders 1
- Therapeutic Area 18
- Musculoskeletal Diseases 1
- Oncology 2
- Hematology 2
- Market Forecast 16
- Respiratory Diseases 1
- Ophthalmology 1
- Orthopedics 1
- Central Nervous System 7
- Inflammatory 1
- Genetic Disorders 1
- Renal Diseases / Nephrology 6
- Endocrinology 1
- Pipeline Analytics Report 1
- Disease Competitive Landscape Monitoring 1